Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma

Journal of the National Cancer Institute

Volumn 99, Issue 1, 2007, Pages 24-31

  Kleinerman, Ruth A ^a   Tucker, Margaret A ^a   Abramson, David H ^b   Seddon, Johanna M ^c   Tarone, Robert E ^d   Fraumeni, Joseph F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^d INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TRETAMINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVOR; CHILD; COMPARATIVE STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FIBROSARCOMA; FOLLOW UP; GENETIC PREDISPOSITION; HISTIOCYTOMA; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; RETINOBLASTOMA; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; STANDARDIZED INCIDENCE RATIO; UNITED STATES; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; CLINICAL TRIAL; EPIDEMIOLOGY; GENETICS; HEALTH SURVEY; INCIDENCE; INFANT; MIDDLE AGED; MULTICENTER STUDY; RADIOTHERAPY; REGISTER; RETINA TUMOR; RISK; RISK ASSESSMENT; SARCOMA; SECOND CANCER; STATISTICS; SURVIVOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; INCIDENCE; INFANT; LEIOMYOSARCOMA; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; POPULATION SURVEILLANCE; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; REGISTRIES; RETINAL NEOPLASMS; RETINOBLASTOMA; RISK ASSESSMENT; SARCOMA; SEER PROGRAM; SURVIVORS; UNITED STATES;

EID: 33846942292     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk002     Document Type: Article

References (43)

1. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al., editors. SEER Cancer Statistics Review, 1975-2003. Bethesda (MD): National Cancer Institute; 2006.
2. Aerts I, Pacquement H, Doz F, Mosseri V, Desjardins L, Sastre X, et al. Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer 2004;40:1522-9.
3. Wong FL, Boice JD, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA 1997;278:1262-7.
4. Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005;23:2272-9.
5. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53:661-71.
6. Moll AC, Imhof SM, Schouten-VanMeeteren AY, Kuik DJ, Hoftnan P, Boers M. Second primary tumors in hereditary retinoblastoma: a register- based follow-up study, 1945-1997. Ophthalmology 2001;108:1109-14.
7. RoartyJD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 1988;95:1583-7.
8. Desjardins L, Haye C, Schlienger P, Laurent M, Zucker JM, Bouquila H. Second non-ocular tumors in survivors of bilateral retinoblastoma. A 30-year follow-up. Ophthalmic Paediatr Genet 1991;12:145-8.
9. Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP, et al. Deletions of a DNA sequence in retinoblastomas and mesenschymal tumors: organization of the sequence and its encoded protein. Proc Nad Acad Sci U S A 1987;84:9059-63.
10. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nature 2003;3:685-94.
11. Brachman DG, Hallahan DE, Beckett MA, Yandell DW, Weichselbaum RR. P53 gene mutations and abnormal retinoblastoma protein in radiation- induced human sarcomas. Cancer Res 1991;51:6393-6.
12. Cance WG, Brennan MF, Dudas ME, Huang CM, Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. NEngl J Med 1990;21:1457-62.
13. Stratton MR, Williams S, Fisher C, Ball A, Westbury G, Guterson BA, et al. Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer 1989;60:202-5.
14. Cohen JA, Geradts J. Loss of Rb and MTS1/CDKKN2 (p16) expression in human sarcomas. Hum Pathol 1997;28:893-8.
15. Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85:1121-8.
16. Li FP, Abramson DH, Tarone RE, Kleinerman RA, Fraumeni JF Jr, Boice JD Jr. Hereditary retinoblastoma, lipoma and second primary cancers. J Natl Cancer Inst 1997;89:83-1.
17. Kleinerman RA, Tarone RE, Abramson DH, Seddon JM, Li FP, Tucker MA. Hereditary retinoblastoma and risk of lung cancer. J Nad Cancer Inst 2000;92:2037-9.
18. World Health Organization. International Classification of Diseases for Oncology 3rd ed. Geneva (Switzerland): Author; 2000. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges. Invest Ophthalmol Vis Sci 2005;46:2684-91.
19. Tucker MA, D'Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317:588-93.
20. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
21. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-11.
22. Mack TM. Sarcomas and other malignancies of soft tissue, retroperito- neum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer 1995; 75:211-14.
23. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504-14.
24. Sedghizadeh PP, Angiero F, Allen CM, Kalmar JR, Rawal Y, Albright EA. Post-irradiation leiomyosarcoma of the maxilla: report of a case in a patient with prior radiation treatment for retinoblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:726-31.
25. Montgomery E, Goldblum JR, Fisher C. Leiomyosarcoma of the head and neck: a clinicopathological study. Histopathology 2002;40:518-25.
26. Klippenstein KA, Wesley RE, Glick AD. Orbital leiomyosarcoma after retinoblastoma [case report]. Ophthalmic Surg Lasers 1999;30:579-83.
27. Venkatraman L, Goepel JR, Steele K, Dobbs SP, Lyness RW, McCluggage WG. Soft tissue, pelvic, and urinary bladder leiomyosarcoma as second neoplasm following hereditary retinoblastoma. J Clin Pathol 2003;56:233-6.
28. Boice JD Jr, Engholm G, Kleinerman RA, Blettner M, Stovall M, Lisco H, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988; 116:3-55.
29. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, et al. Cancer incidence in atomic bomb survivors. Part II: solid tumors, 1958-1987. Radiat Res 1994;137:S17-67.
30. Zhai YL, Nikaido T, Orii A, Horiuchi A, Toki T, Fujii S. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol 1999;75:453-9.
31. Lefevre S-H, Vogt N, Dutrillaux A-M, Chauveinc L, Stoppa-Lyonnet D, Doz F, et al. Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma. Oncogene 2001;20: 8092-9.
32. Brucker B, Ernst, Meadows A, Zderic S. A second leiomyosarcoma in the urinary bladder of a child with a history of retinoblastoma 12 years following partial cystectomy. Pediatr Blood Cancer 2006;46:811-4.
33. Schneider-Stock R, Boltze C, Jaeger V, Stumm M, Seiler C, Rys J, et al. Significance of loss of heterozygosity of the RBI gene during tumour progression in well-differentiated liposarcomas. J Pathol 2002;197:654-60.
34. Reider H, Lohmann D, Poensgen B, Fritz B, Asian M, Drohm D, et al. Loss of heterozygosity of the retinoblastoma (RBI) gene in lipomas from a retinoblastoma patient. J Nad Cancer Inst 1998;90:324-6.
35. Schlienger P, Campana F, Vilcoq JR, Asselain B, Dendale R, Desjardins L, et al. Nonocular second primary tumors after retinoblastoma: retrospective study of 111 patients treated with electron beam radiotherapy with or without TEM. Am J Clin Oncol 2004;27:411-9.
36. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Nad Cancer Inst 2001;93:618-29.
37. Menu-Branthomme A, Rubino C, Shamsaldin A, Hawkins MM, Grimaud E, Dondon MG, et al. Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood. Int J Cancer 2004; 110:87-93.
38. Bisogno G, Sotti G, Nowicki Y, Ferrari A, Garaventa A, Zanetti I, et al. Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group. Cancer 2004;100:1758-65.
39. Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 2005;103:2391-6.
40. Jenkinson HC, Hawkins MM, Stiller CA, Winter DL, Marsden HB, Stevens MCG. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer 2004;91:1905-10.
41. Robinson E, Neugut Al, Wylie P. Clinical aspects of postirradiation sarcomas. J Natl Cancer Inst 1988;80:233-10.
42. Tucker MA, Boice JD, Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone and eye in Connecticut, 1935-82. Nad Cancer Inst Monogr 1985;68:161-89.
43. Berking C, Brady MS. Cutaneous melanoma in patients with sarcoma. Cancer 1997:79:843-8.